News

29 November 2021

BAP Pharma awarded Thames Valley 250 Special Recognition Award

BAP Pharma are the proud recipients of the Thames Valley 250 Special Recognition Award.

The Thames Valley 250 Special Recognition Award is presented to a company that has shown outstanding achievement, innovation and commitment, while significantly contributing to the Thames Valley economy and the wider community.

In 2020, BAP Pharma were ranked 47th on the Thames Valley 250 list, which comprises of the top privately owned businesses (by turnover) headquartered in the region, which led to our nomination for the Special Recognition Award.

“We were very impressed with their overall strategy and the leadership quality and skills that were demonstrated across the business. In a highly compliant and regulated industry, they demonstrated a clear vision to build trust with their customers and look for solutions with customer excellence as their end goal.”

Judge’s Feedback.

2021 has been another year of growth and considerable success for BAP Pharma.

We have expanded our core business operations internationally, with the commencement of operations at our facility in Germany and we have relocated our UK HQ to a new prestigious, state of the art facility and will soon relocate our US operations into a newer and much larger facility, that is better equipped to manage our ongoing growth and diversification.

We have major plans for continued growth, diversification and success, ensuring BAP Pharma continues to provide a high-quality service to our customers and provide a platform for our employees to continually excel and succeed.

“My priority has been to continuously motivate staff. We have had to think of new ways of doing this and making ourselves accessible. And we have looked for alternative solutions to grow the business during the pandemic. For example, with many countries taking a nationalist approach and not sharing vaccines we have had to look for different markets, including the Far East and Latin America. We have introduced two new divisions to the business and achieved record growth of 50% last year. We are looking to grow 40% next year.”

Dr. Bashir Pakar, Founder and Managing Director of BAP Pharma.

 

Please click here to read the full Business Magazine article

You Might Also Like

Exclusive Agreement For The Supply and Distribution Of Bicillin® LA

BAP Pharma Limited is pleased to announce the signing of an exclusive agreement for the supply and distribution of Bicillin® L-A (Penicillin G Benzathine) to expand access to the product in the UK and Europe (previously only available in the US)   Product Details Bicillin® L-A is a ready-to-use Benzathine

Exclusive Agreement For The Supply and Distribution Of Bicillin® LA

BAP Pharma ranked in FEBE Growth 100 List

BAP Pharma are honoured to receive an award from FEBE Growth 100 and to have been ranked within the 2022 list of the fastest growing, founder-led, privately-owned UK businesses. BAP Pharma receiving the FEBE Growth 100 Award – pictured left to right – Award Partner Anthony Higson from Pictet, FEBE

BAP Pharma ranked in FEBE Growth 100 List

BAP Pharma Appointed An Export Champion

BAP Pharma are proud to announce that our UK General Manager – Rebecca Bibby – has been appointed an Export Champion for the Southeast, by the Department for Business and Trade (DBT) and has been invited to join the Export Champions programme – a vital element of the UK Government’s

BAP Pharma Appointed An Export Champion